Best Momentum Stock to Buy for July 7th

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, July 7th:

Verona Pharma VRNA: This company which is focused on developing and commercializing innovative therapeutics for the treatment of patients burdened with chronic respiratory diseases with significant unmet medical needs, has a Zacks Rank #1(Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 37.5% over the last 60 days.

Verona Pharma PLC American Depositary Share Price and Consensus

Verona Pharma PLC American Depositary Share price-consensus-chart | Verona Pharma PLC American Depositary Share Quote

Verona Pharma’s shares gained 69% over the last three month compared with the S&P 500’s gain of 26%. The company possesses a Momentum Score of A.

Verona Pharma PLC American Depositary Share Price

Verona Pharma PLC American Depositary Share price | Verona Pharma PLC American Depositary Share Quote

Evolv Technologies EVLV: This company which offer an array of AI touchless screening technologies for weapons detection, identity verification and health-related threats through Evolv Cortex AI(TM) software platform, has a Zacks Rank #1, and witnessed the Zacks Consensus Estimate for its current year earnings increasing 23.3% over the last 60 days.

Evolv Technologies Holdings, Inc. Price and Consensus

Evolv Technologies Holdings, Inc. price-consensus-chart | Evolv Technologies Holdings, Inc. Quote

Evolv Technologies' shares gained 100.7% over the last three month compared with the S&P 500’s gain of 25.9%. The company possesses a Momentum Score of B.

Evolv Technologies Holdings, Inc. Price

Evolv Technologies Holdings, Inc. price | Evolv Technologies Holdings, Inc. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research